ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2022

Zinzino group revenue increased with a total of 13%, compared with the previous year.

The revenue in November for Zinzino's sales markets increased by 13% and amounted to SEK 159.6 (140.8) million. Faun Pharma's external sales increased by 5% and amounted to SEK 5.8 (5.5) million. Overall, the Group increased revenues by 13% to SEK 165.4 (146.3) million compared with the previous year.

Accumulated revenue for January – November 2022 increased by 7% to SEK 1312.6 (1222.4) million.

Revenues were distributed as follows:

Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden

-Central Europe: Austria, Germany, Switzerland

-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania

-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland

-The Baltics: Estonia, Latvia, Lithuania

-North America: Canada, USA

-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

-Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:

marketing@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se

This disclosure contains information that Zinzino is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-12-2022 11:00 CET.